Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DQ8S | ISIN: US6904691010 | Ticker-Symbol: 1OT
Frankfurt
27.06.25 | 08:05
0,238 Euro
+5,31 % +0,012
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OVID THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
OVID THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2600,28013:03
0,2620,28627.06.

Aktuelle News zur OVID THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
OVID THERAPEUTICS Aktie jetzt für 0€ handeln
MiOvid Therapeutics Inc. - 8-K, Current Report-
MiOvid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties204NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions...
► Artikel lesen
05.06.Ovid Therapeutics Inc.: Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025-
13.05.Ovid Therapeutics GAAP EPS of -$0.14 in-line, revenue of $0.13M beats by $0.1M3
13.05.Ovid Therapeutics Inc. - 10-Q, Quarterly Report2
13.05.Ovid Therapeutics Inc. - 8-K, Current Report2
02.05.Ovid Therapeutics Inc. - 8-K, Current Report2
24.03.BTIG cuts Ovid Therapeutics stock price target to $42
11.03.Ovid Therapeutics Inc. - 10-K, Annual Report-
11.03.Ovid Therapeutics GAAP EPS of -$0.13 beats by $0.03, revenue of $0.07M misses by $0.12M1
05.03.Ovid Therapeutics Inc. - 8-K, Current Report-
03.03.Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors3
13.02.Ovid Therapeutics Inc. - 8-K, Current Report-
11.09.24Ovid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth480NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions...
► Artikel lesen
13.08.24Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results421Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific Advisory Board under the leadership of Dr....
► Artikel lesen
01.07.24Ovid Therapeutics Inc.: Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations179The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1